Trial · NCT01215357
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
NCT01215357, Phase 2, Completed, Emalex Biosciences Inc.; results first posted 2013-02-12
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble. Trials, record NCT01215357. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01215357
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
- NCT number
- NCT01215357
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 34 participants, actual
- Lead sponsor
- Emalex Biosciences Inc.
- Conditions
- Pathological Gambling
- Interventions
- Ecopipam
- First posted
- 2010-10-06
- Last updated
- 2024-05-14
- Results first posted
- 2013-02-12
- Limitations and caveats
This was an open label trial of ecopipam for the treatment of pathological gambling. A significant effect of drug treatment was demonstrated. These data need to be verified with a double-blind, placebo controlled trial.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Statistically Significant (p<0.05) Decrease From Baseline in Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling | Baseline and 6 weeks | This scale assesses the severity of gambling urges and gambling behaviors. The study anticipates that there will be a reduction in either or both of these assessments. The range is from a minimum of 0 to a maximum of 40, where zero means no gambling urges occurred. |
| Secondary | Type, Frequency and Severity of Side Effects | 6 weeks | All side effects of the drug will be monitored and recorded |
| Secondary | Statistically Significant Changes in the Gambling Symptom Assessment Scale | 6 weeks | It is expected that there will be decreases in this scale |
| Secondary | Effects on the Clinical Global Impression | 6 weeks | Clinician's Global Impression is used assess severity and changes in clinical symptoms during and at the end of the study |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Statistically Significant (p<0.05) Decrease From Baseline in Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling | Baseline and 6 weeks | Patients completing all visits | YBOCS score | MEAN |
| SECONDARY | Type, Frequency and Severity of Side Effects | 6 weeks | |||
| SECONDARY | Statistically Significant Changes in the Gambling Symptom Assessment Scale | 6 weeks | |||
| SECONDARY | Effects on the Clinical Global Impression | 6 weeks |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Statistically Significant (p<0.05) Decrease From Baseline in Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling | Ecopipam 50 mg or 100 mg as Needed | 13.9 | Standard Deviation 8.79 | YBOCS score |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ecopipam (50 or 100 mg, as Needed) | 34 | |
| Overall Study | COMPLETED | Ecopipam (50 or 100 mg, as Needed) | 22 | |
| Overall Study | NOT COMPLETED | Ecopipam (50 or 100 mg, as Needed) | 12 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Sedation | Nervous system disorders | Ecopipam 50 or 100 mg, as Needed | 4 | 34 | 4 |
| other | Anxiety | Nervous system disorders | Ecopipam 50 or 100 mg, as Needed | 3 | 34 | 3 |
| other | Constipation | Gastrointestinal disorders | Ecopipam 50 or 100 mg, as Needed | 2 | 34 | 2 |
| other | Rhinorrhea | Eye disorders | Ecopipam 50 or 100 mg, as Needed | 2 | 34 | 2 |
| other | Vomiting | Gastrointestinal disorders | Ecopipam 50 or 100 mg, as Needed | 2 | 34 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ecopipam 50 or 100 mg, as Needed | ||
| Total, other adverse events | Ecopipam 50 or 100 mg, as Needed | 13 | 34 |
| Total, serious adverse events | Ecopipam 50 or 100 mg, as Needed | 0 | 34 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25166480 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01215357
GET https://conductscience.org/api/trials/v1/NCT01215357/registered